An observational study in Cancer (Solid Tumors) and Interaction Drug Food, sponsored by Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI). Recruiting at 1 site in Morocco. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-26.
Sponsored by Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI) · Observational
The goal of this observational study is to To assess the prevalence and patterns of dietary supplement use among patients with cancer and to analyze the impact of these supplements in the context of anticancer medical treatments, including chemotherapy, targeted therapies, hormone therapy, and immunotherapies.
The main questions it aims to answer :
Participants will:
10,818 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 200 across 2,638 observational studies indexed under Neoplasms.
Browse Neoplasms studies →This is the only study on the registry with Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI) as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Adult patients diagnosed with cancer and receiving medical anticancer treatment (chemotherapy, hormone therapy, immunotherapy, or targeted therapy) at the study site. Participants will be assessed for dietary supplement use, tolerance, and potential interactions between dietary supplements and anticancer medications.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Behavioral: Dietary Supplement Use Assessment
Participants will complete a structured face-to-face questionnaire on dietary supplement use, reasons for Use, frequency and duration of use, perceived adverse effects, and concomitant anticancer treatments.
Prevalence of Dietary Supplement Use and Tolerance
Assessment of the prevalence of dietary supplement use among cancer patients and evaluation of adverse effects associated with dietary supplement consumption.
Time frame: At enrollment
Potential Drug-Supplement Interactions
Assessment of potential interactions between dietary supplements and anticancer medications
Time frame: At enrollment or single study visit
Potential Drug-Supplement Interactions Assessed by Artificial Intelligence
Assessment of potential interactions between dietary supplements and anticancer treatments using Hedrine software.
Time frame: At enrollment or Single study visit
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.